Mark Corrigan

Mark H.
N.
Corrigan was the founder of Tremeau Pharmaceuticals, Inc., founded in 2016, where the title held was President-Research & Development from 2016 to 2017.
Current jobs include Chairman at Exacis Biotherapeutics, Inc. since 2020; Independent Director at Wave Life Sciences Ltd. since 2019; Director at Wave Life Sciences USA, Inc. since 2019; Director at Perseus Holdings USA LLC since 2020; Scientific Advisor at Brighton Biotech, Inc.; and President at Silver Creek Pharmaceuticals, Inc. since 2024.
Former jobs include Chief Executive Officer & Director at Correvio Pharma Corp.
from 2019 to 2020; President & Chief Executive Officer at CombinatoRx, Inc. in 2010; President, Chief Executive Officer & Director at Zalicus, Inc. from 2011 to 2014; Chairman at EPIRUS Biopharmaceuticals, Inc. from 2014 to 2016; Executive Chairman at Novelion Therapeutics, Inc. from 2018 to 2019; Chairman at Elios Therapeutics LLC; Independent Director at Cubist Pharmaceuticals LLC from 2011 to 2015; Independent Director at Avanir Pharmaceuticals, Inc. from 2014 to 2015; Director at CoLucid Pharmaceuticals, Inc. from 2015 to 2017; Director at Synereca Pharmaceuticals, Inc.; Director at Neuromed Pharmaceuticals Ltd.; Lead Independent Director at BlackThorn Therapeutics, Inc. from 2018 to 2019; Director at Quartet Medicine, Inc.; Independent Director at Nabriva Therapeutics Plc from 2017 to 2020 and from 2021 to 2023; Independent Director at Trevena, Inc. from 2023 to 2024; Director at Pamlico BioPharma, Inc.; Group Vice President-Global Clinical Research at Pharmacia & Upjohn, Inc. from 1993 to 2003; Executive Vice President-Research & Development at Sumitomo Pharma America, Inc. from 2003 to 2009; Member-Supervisory Board at Nabriva Therapeutics GmbH from 2016 to 2017; and Principal at UNC School of Medicine.
Education includes undergraduate and doctorate degrees from the University of Virginia.